GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Camurus AB (OTCPK:CAMRF) » Definitions » Total Liabilities

CAMRF (Camurus AB) Total Liabilities : $48.0 Mil (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Camurus AB Total Liabilities?

Camurus AB's Total Liabilities for the quarter that ended in Jun. 2024 was $48.0 Mil.

Camurus AB's quarterly Total Liabilities declined from Dec. 2023 ($40.44 Mil) to Mar. 2024 ($39.87 Mil) but then increased from Mar. 2024 ($39.87 Mil) to Jun. 2024 ($48.03 Mil).

Camurus AB's annual Total Liabilities increased from Dec. 2021 ($25.63 Mil) to Dec. 2022 ($29.95 Mil) and increased from Dec. 2022 ($29.95 Mil) to Dec. 2023 ($40.44 Mil).


Camurus AB Total Liabilities Historical Data

The historical data trend for Camurus AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Camurus AB Total Liabilities Chart

Camurus AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.89 23.52 25.63 29.95 40.44

Camurus AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.37 31.88 40.44 39.87 48.03

Camurus AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Camurus AB's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=35.934+(1.327+4.4408920985006E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+3.179)
=40.4

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=185.991-145.551
=40.4

Camurus AB's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=40.886+(1.011+-1.7763568394003E-15
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+6.136)
=48.0

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=327.269-279.236
=48.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Camurus AB Total Liabilities Related Terms

Thank you for viewing the detailed overview of Camurus AB's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Camurus AB Business Description

Traded in Other Exchanges
Address
Ideon Science Park, Lund, SWE, SE-223 70
Camurus AB is a research and development-focused pharmaceutical company. It develops pharmaceuticals for the treatment of serious and chronic diseases such as opioid addiction, pain, cancer, and endocrine diseases. The Camurus' clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company's product pipeline includes CAM2029, CAM4072 and CAM2043.

Camurus AB Headlines